TPX-0131, a Potent CNS-penetrant, Next-generation Inhibitor of Wild-type ALK and ALK-resistant Mutations

Since 2011, with the approval of crizotinib and subsequent approval of four additional targeted therapies, anaplastic lymphoma kinase (ALK) inhibitors have become important treatments for a subset of patients with lung cancer. Each generation of ALK inhibitor showed improvements in terms of central...

Descripción completa

Detalles Bibliográficos
Autores principales: Murray, Brion W., Zhai, Dayong, Deng, Wei, Zhang, Xin, Ung, Jane, Nguyen, Vivian, Zhang, Han, Barrera, Maria, Parra, Ana, Cowell, Jessica, Lee, Dong J., Aloysius, Herve, Rogers, Evan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Association for Cancer Research 2021
Materias:
MCT First Disclosures
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398166/
https://www.ncbi.nlm.nih.gov/pubmed/34158340
http://dx.doi.org/10.1158/1535-7163.MCT-21-0221

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9398166/
https://www.ncbi.nlm.nih.gov/pubmed/34158340
http://dx.doi.org/10.1158/1535-7163.MCT-21-0221

Ejemplares similares